Globus Medical extends versatility of Advanced Materials Science™ anterior interbody portfolio with launch of COHERE™ ALIF Spacer and Modulus™ ALIF Blades

$GMED
Medical/Dental Instruments
Health Care
Get the next $GMED alert in real time by email

AUDUBON, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, today announced two commercial launches:

  1. COHERE™ ALIF Spacer: The first Porous PEEK™ interbody spacer for anterior lumbar interbody fusion (ALIF) surgery, and
  2. Modulus™ ALIF Blades: An extension of the market-leading Modulus™ ALIF interbody spacer system.

The COHERE ™ ALIF Spacer is the latest addition to Globus Medical's Advanced Materials Science™ (AMS) implant portfolio, featuring proprietary porous surface technology designed for bone in-growth while maintaining the imaging and mechanical properties favored in a solid PEEK interbody spacer.1,2

"Porous PEEK combines the stiffness and radiolucency of PEEK with the osseointegration potential offered by the porous technology,"1,3 said Frank Phillips, MD, professor of orthopedic surgery and fellowship director of the Division of Spine Surgery at Rush University Medical Center in Chicago. "The enhanced clinical outcomes possible with Cohere™ Porous PEEK for anterior cervical fusionand the comprehensive surface technology options available are now also helping to advance patient care for anterior lumbar spine surgery. In addition, the ability to radiographically assess fusion is a significant clinical benefit."

Modulus™ ALIF Blades extend the versatility of the Modulus™ ALIF Spacer portfolio by offering surgeons different fixation options with the same interbody spacer. Procedural efficiency is achieved with Modulus™ ALIF Blades through the ability to deliver anchoring blade fixation immediately following interbody spacer placement to reduce the number of surgical steps and instruments needed in the procedure. 

"Modulus™ ALIF with the anchoring blade option makes anterior spine surgery even more efficient while potentially reducing complications by reducing the number of instrument passes adjacent to major vessels," said Anthony Kwon, MD, Orthopedic Spine Surgeon practicing at OrthoCarolina's Spine Center and Atrium Medical Center in Charlotte, NC. "The low-profile instrumentation and streamlined delivery of fixation also helps to reduce the exposure window traditionally needed for anterior surgery, allowing for a more minimally invasive approach".

These two new offerings strengthen Globus Medical's comprehensive anterior spine portfolio, designed to address a variety of the most challenging procedures in spine surgery. The integration of a Porous PEEK interbody spacer option and Modulus anchor fixation demonstrate Globus Medical's commitment to providing surgeon partners with procedurally integrated ALIF solutions.

"These products underscore our commitment to advancing surgical outcomes and providing spine surgeons with best-in-class solutions that span varying patient anatomy and surgeon preference to provide the best possible care in their hands," said David Hole, president of Spine at Globus Medical. "We remain dedicated to delivering innovation through our product development engine to solve the unmet clinical needs of our surgeon partners while helping to improve patient care."

About Globus Medical, Inc.

Globus Medical, Inc. is a leading global musculoskeletal company dedicated to solving unmet clinical needs and changing lives. We innovate with inspired urgency, provide world-class education and clinical support, and advance care throughout spine, orthopedic trauma, joint reconstruction, biomaterials and enabling technologies. Additional information can be accessed at https://www.globusmedical.com/.



References:

1. Evans NT, Torstrick FB, Lee CS, et al. High-strength, surface-porous polyether-ether-ketone for load-bearing orthopedic implants. Acta Biomater 2015;13:159-67.

2. Torstrick FB, Lin ASP, Potter D, et al. Porous PEEK improves the bone-implant interface compared to plasma-sprayed titanium coating on PEEK. Biomaterials 2018;185:106-16

3. Torstrick FB, Evans NT, Stevens HY, et al. Do surface porosity and pore size influence mechanical properties and cellular response to PEEK? Clin Orthop Relat Res 2016;474(11):2373-83.

4. Hill CP and Strenge KB. Early clinical outcomes comparing porous PEEK, smooth PEEK, and structural allograft interbody devices for anterior cervical discectomy and fusion. J Spine Neurosurg 2019;8(1):1-7.

Safe Harbor Statements 

All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as "believe," "may," "might," "could," "will," "aim," "estimate," "continue," "anticipate," "intend," "expect," "plan" and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, the risks and costs associated with the integration of, and the ability of Globus Medical and NuVasive to integrate, their businesses successfully and to achieve anticipated synergies, health epidemics, pandemics and similar outbreaks, including the COVID-19 pandemic, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to comply with laws and regulations that are or may become applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, and other risks. For a discussion of these and other risks, uncertainties and other factors that could affect our results, you should refer to the disclosure contained in our most recent annual report on Form 10-K filed with the Securities and Exchange Commission, including the sections labeled "Risk Factors" and "Cautionary Note Concerning Forward-Looking Statements," and in our Forms 10-Q, Forms 8-K and other filings with the Securities and Exchange Commission. These documents are available at www.sec.gov. Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. We undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.

Investor contact:

Brian Kearns

610-930-1800

investors@globusmedical.com

Media contact:

Moran Chavez

media@globusmedical.com



Primary Logo

Get the next $GMED alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$GMED

DatePrice TargetRatingAnalyst
1/10/2025$97.00Underperform → Neutral
BofA Securities
12/2/2024$83.00 → $100.00Equal-Weight → Overweight
Morgan Stanley
8/7/2024$60.00 → $78.00Equal Weight → Overweight
Wells Fargo
5/20/2024$60.00 → $80.00Neutral → Overweight
Piper Sandler
3/18/2024$60.00Neutral → Buy
BTIG Research
10/20/2023$75.00Buy
ROTH MKM
9/19/2023$61.00Hold → Buy
Stifel
3/30/2023$67.00Hold → Buy
Canaccord Genuity
More analyst ratings

$GMED
Press Releases

Fastest customizable press release news feed in the world

See more
  • Globus Medical extends versatility of Advanced Materials Science™ anterior interbody portfolio with launch of COHERE™ ALIF Spacer and Modulus™ ALIF Blades

    AUDUBON, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, today announced two commercial launches: COHERE™ ALIF Spacer: The first Porous PEEK™ interbody spacer for anterior lumbar interbody fusion (ALIF) surgery, andModulus™ ALIF Blades: An extension of the market-leading Modulus™ ALIF interbody spacer system. The COHERE ™ ALIF Spacer is the latest addition to Globus Medical's Advanced Materials Science™ (AMS) implant portfolio, featuring proprietary porous surface technology designed for bone in-growth while maintaining the imaging and mechanical properties favored in a solid PEEK interbody spacer.1,2 "Porous

    $GMED
    Medical/Dental Instruments
    Health Care
  • Globus Medical to feature ExcelsiusFlex™ for Total Knee Arthroplasty at the American Academy of Orthopedic Surgeons Annual Meeting

    AUDUBON, Pa., March 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, today announced it will participate in the 2025 Annual Meeting of the American Academy of Orthopedic Surgeons (AAOS) in San Diego, Calif., from March 10-14, 2025. Join Globus at booth #2517 to learn about the comprehensive Globus Medical product portfolio across Spine, Trauma, and Joint Reconstruction procedures; Enabling Technology; Power Tools; and Regenerative Biomaterials segments. Globus will be featuring one of its latest technology innovations, the ExcelsiusFlex™ surgical robotic navigation system for Total Knee Arthroplasty (TKA), alongside its Total Jo

    $GMED
    Medical/Dental Instruments
    Health Care
  • Globus Medical to participate in the Canaccord Genuity 2025 Musculoskeletal Conference

    AUDUBON, Pa., March 05, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, today announced it is scheduled to participate in the Canaccord Genuity 2025 Musculoskeletal Conference in San Diego. Management is scheduled to present on Monday, March 10, 2025 at 4:30 pm PT. Interested parties can access the live and archived webcast of the presentation in the "News & Events", "Events & Webcasts" section of the Globus Medical investor relations website at https://www.investors.globusmedical.com/news-events/events-webcasts.   About Globus Medical, Inc. Based in Audubon, Pennsylvania, Globus Medical, Inc. is a leading global musculoskeletal te

    $GMED
    Medical/Dental Instruments
    Health Care

$GMED
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$GMED
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$GMED
SEC Filings

See more

$GMED
Leadership Updates

Live Leadership Updates

See more
  • Dentsply Sirona Appoints Michael Barber and Daniel Scavilla as New Board Members

    CHARLOTTE, N.C., Feb. 06, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that Michael J. Barber and Daniel T. Scavilla have been appointed to its Board of Directors (the "Board"), effective February 5, 2025. Mr. Barber brings over 40 years of experience in product management and innovation, including executive leadership roles at GE, where he was responsible for the transformation of the company's digital X-Ray program. Mr. Scavilla, currently CEO of Globus Medical, is a seasoned executive with a deep skillset in commercial deployment and business integration, having successfully led the merger of Globus and NuVasive. Mr. B

    $EXAS
    $GE
    $GMED
    $XRAY
    Medical Specialities
    Health Care
    Consumer Electronics/Appliances
    Technology
  • IMPULSE DYNAMICS APPOINTS FIVE NEW BOARD MEMBERS

    MARLTON, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Impulse Dynamics N.V., a company dedicated to improving the lives of people with heart failure (HF), today announced the election of five new members to its Board of Directors at the most recent meeting of its shareholders.  "We are extremely pleased to have Jim Tobin, Joe Capper, Glenn Muir, John Bakewell, and Dan Scavila all joining our board of directors," said Prof. Shlomo Ben-Haim, Chairman of the Board and Founder of Impulse Dynamics.  "This is an illustrious group to be adding to the board, and I am extremely pleased to be welcoming and working with all of them as we rapidly advance our goals for the company, for CCM therapy, and mo

    $BEAT
    $GMED
    $GTHX
    $HOLX
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Medical Electronics
  • Axonics® Announces Appointment of David M. Demski to Board of Directors

    IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today announced the appointment of veteran medical technology industry executive David M. Demski to its board of directors, effective January 1, 2021. Mr. Demski currently serves as president and CEO of Globus Medical, Inc. (Nasdaq: GMED), a publicly traded medical technology company that manufactures and markets musculoskeletal implants and related surgical products, with sales in 2019 of over $750 million and a curren

    $AXNX
    $GMED
    Medical/Dental Instruments
    Health Care

$GMED
Financials

Live finance-specific insights

See more
  • Nevro Reports Fourth-Quarter and Full-Year 2024 Financial Results

    REDWOOD CITY, Calif., March 4, 2025 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its fourth-quarter and full-year 2024 financial results. "We are pleased that adjusted EBITDA for the full-year 2024 came in ahead of our revised expectations and that our balance sheet remains strong, reflecting our ongoing focus on working capital management and the benefits from our 2024 restructurings," said Kevin Thornal, Nevro's president and CEO. "Importantly, we look forward to joining forces with Globus Medical to achieve our full potential and working together to free

    $GMED
    $NVRO
    Medical/Dental Instruments
    Health Care
  • Globus Medical Reports Fourth Quarter and Full Year 2024 Results

    AUDUBON, Pa., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, today announced its financial results for the fourth quarter and year ended December 31, 2024. Fourth Quarter 2024: Worldwide net sales were $657.3 million, an increase of 6.6% on an as-reported basis and an increase of 6.9% on a constant currency basisGAAP net income for the quarter was $26.5 millionGAAP diluted earnings per share ("EPS") was $0.19 and non-GAAP diluted EPS was $0.84Non-GAAP adjusted EBITDA was $196.9 million, or 30.0% of net sales Full Year 2024: Worldwide net sales were $2,519.4 million, an increase of 60.6% on an as-reported basis a

    $GMED
    Medical/Dental Instruments
    Health Care
  • Globus Medical to Acquire Nevro Corp. to Expand Treatment Options for Patients

    AUDUBON, Pa. and REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical (NYSE:GMED), a leading musculoskeletal solutions company, and Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced they have entered into a definitive agreement for Globus Medical to acquire all shares of Nevro in an all-cash transaction. Under the terms of the agreement, which was unanimously approved by the boards of directors of both companies, Globus Medical will acquire all shares of Nevro for $5.85 per share. The transaction represents a total equity value of approximately $250 million.

    $GMED
    $NVRO
    Medical/Dental Instruments
    Health Care

$GMED
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more